Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Qiagen N.V.    QGEN   NL0012169213

QIAGEN N.V.

(QGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

COVID-19: More testing kits desperately needed - NCDC

04/28/2020 | 12:53pm EST

Director-General, Nigeria Centre for Disease Control, Chikwe Ihekweazu, says Nigeria is desperately in need of more ribonucleic acid COVID-19 test kits.

In a tweet on Sunday, the NCDC boss said this became important as the country expanded testing for the virus.

'We're desperately looking for more RNA extraction kits as we expand #COVID19 testing.

'Product: Total viral RNA extraction kits (preferably spin column and with a lysis buffer). Manufacturers: Qiagen, ThermoFischer, SeeGene, Inqaba, LifeRiver etc,' he said.

The centre as of 11:50 pm, April 26 confirmed 91 new cases of COVID-19 in the country bringing the total of confirmed cases to 1273.

© Pakistan Press International, source Asianet-Pakistan

Stocks mentioned in the article
ChangeLast1st jan.
QIAGEN N.V. -0.53% 52.1 Delayed Quote.-1.42%
SEEGENE INC End-of-day quote.
All news about QIAGEN N.V.
01/26QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
01/26QIAGEN N.V. : to Report Fourth Quarter and Full-Year 2020 Results
BU
01/21QIAGEN NV : Warburg Research remains Neutral
MD
01/20QIAGEN N : Confirms COVID-19 Test Accuracy Amid Mutations, to Resubmit Antigen T..
MT
01/20QIAGEN N : Plans to Resubmit EUA Submission in the U.S. for QIAreach SARS-CoV-2 ..
BU
01/20QIAGEN N : Confirms Effectiveness of Its SARS-CoV-2 PCR Tests in the Face of Mut..
BU
01/19QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
01/19DGAP-PVR : QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [..
DJ
01/08DGAP-PVR : QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [..
DJ
01/08QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
More news
Financials (USD)
Sales 2020 1 876 M - -
Net income 2020 294 M - -
Net Debt 2020 1 069 M - -
P/E ratio 2020 41,0x
Yield 2020 -
Capitalization 11 848 M 11 848 M -
EV / Sales 2020 6,89x
EV / Sales 2021 5,83x
Nbr of Employees 5 300
Free-Float 93,0%
Chart QIAGEN N.V.
Duration : Period :
Qiagen N.V. Technical Analysis Chart | QGEN | NL0012169213 | MarketScreener
Technical analysis trends QIAGEN N.V.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 56,92 $
Last Close Price 52,10 $
Spread / Highest target 26,7%
Spread / Average Target 9,25%
Spread / Lowest Target -21,3%
EPS Revisions
Managers and Directors
NameTitle
Thierry Bernard Chief Executive Officer
Lawrence A. Rosen Chairman-Supervisory Board
Barthold Piening Senior Vice President & Head-Global Operations
Roland Sackers Chief Financial Officer & Managing Director
Metin Colpan Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
QIAGEN N.V.-1.42%11 848
MODERNA, INC.49.07%61 624
LONZA GROUP AG3.66%49 275
CELLTRION, INC.-10.58%40 532
IQVIA HOLDINGS INC.-3.44%33 169
SEAGEN INC.-7.11%29 430